Diabetes

Weed's role as a natural painkiller without the addictive properties of opioids is well-known, as is cannabidiol's helpfulness in combating seizures and anxiety.  Studies and evidence support CBD's effectiveness in improving the behavior of children on the autism spectrum...

Sanofi SA (ADR) (NYSE: SNY), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical company.  The Analyst Analyst Graham Parry upgraded Sanofi from Neutral to Buy and...

Automation and artificial intelligence are transforming everything from travel to finance to how garage doors are closed. The management of personal health is poised for similar disruption. Fitbit Inc (NYSE: FIT) and Apple Inc. (NASDAQ: AAPL) have taken wearable-based health monitoring mainstream...

Valeritas Holdings Inc (NASDAQ: VLRX), a medical technology company known for its V-Go Wearable Insulin Delivery device, could more than double in value, according to Oppenheimer. The Analyst Oppenheimer's Steven Lichtman initiated coverage of Valeritas with an Outperform rating and 12- to 18-...

Tandem Diabetes Care Inc (NASDAQ: TNDM) shares were rallying Friday following FDA approval of the company's new insulin pump.  Tandem Diabetes were trading up 12.4 percent to $22.83 at the time of publication Friday morning. What Happened The medical device maker...

Tandem Diabetes Care Inc (NASDAQ: TNDM), a medical technology company focused on the treatment of diabetes and insulin infusion therapy, has seen transformed from a "solid competitive" company in mid-2016 to one where it might not survive, according to Baird. But the company may boast the...

Analysts at Credit Suisse downgraded Eli Lilly and Co (NYSE: LLY) in October and just three months later, the firm believes another downgrade is warranted. The Analyst Credit Suisse's Vamil Divan downgraded Eli Lilly's stock from Neutral to Underperform with a price target lowered...

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.  The Analyst Goldman Sachs' Jami Rubin...

Raymond James identified four major tailwinds for Insulet Corporation (NASDAQ: PODD) that the firm said could help drive 20-percent-plus revenue growth over the next two years. The Analyst Raymond James analyst Jayson Bedford upgraded Insulet from Market Perform from Outperform with an $80...

Flexion Therapeutics Inc (NASDAQ: FLXN) announced last week it has received regulatory approval for its Zilretta therapy represents a "monumental milestone" for the company, BMO Capital Markets analyst Gary Nachman commented in a research report. The analyst maintains an Outperform rating on...

Despite a more than 35 percent plunge in DexCom, Inc. (NASDAQ: DXCM)'s stock, analysts at Canaccord Genuity continue to hold a bullish outlook. The firm's Kyle Rose maintains a Buy on DexCom's stock with a price target lowered from $90 to $69. DexCom's stock was hard hit on Thursday...

According to a CNBC report, Apple Inc. (NASDAQ: AAPL) created a secret team that is tasked with treating diabetes. CNBC, citing "people familiar with the matter," reported that Steve Jobs himself envisioned the project prior to his death. Today, the "super secret" initiative appears to be in full...

SkyTides on Friday continued its assault Friday on Insulet Corporation (NASDAQ: PODD) by releasing yet another report containing allegations of deceptive behavior within the company. The new report focuses on information that Insulet’s president Shacey Petrovic supplied to shareholders....

Eli Lilly and Co (NYSE: LLY) detailed in a presentation to the investment community its outlook for new product launches through 2023. Eli Lilly said that it has the potential to launch a total of 20 new products in the 10-year period beginning in 2014 and extending through 2023. In addition, the...

Rodman & Renshaw analyst Raghuram Selvaraju believes LabStyle Innovations Corp (NASDAQ: DRIO) could more than double in a year from the current levels. The brokerage initiated coverage with a rating of Buy and a price target of $12.00 on valuation. The optimism was due to the development of an...